AOP Health just dropped some big news at the ASH 2025 congress—two new studies on rare blood cancers could change the game for patients with essential thrombocythemia and polycythemia vera. Their treatment, ropeginterferon alfa-2b, is showing promise for people who haven’t had many options. Love seeing real progress for rare disease warriors! #Health #BodyHealth #BloodCancer